Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects
U. Urner‐Bloch, Martin Urner, Nicoletta F. Jaberg-Bentele, et al.
European Journal of Cancer (2016) Vol. 65, pp. 130-138
Open Access | Times Cited: 68

Showing 1-25 of 68 citing articles:

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer, Paolo A. Ascierto, Helen Gogas, et al.
The Lancet Oncology (2018) Vol. 19, Iss. 10, pp. 1315-1327
Closed Access | Times Cited: 524
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
Eric Van Cutsem, Sanne C.F.A. Huijberts, Axel Grothey, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 17, pp. 1460-1469
Open Access | Times Cited: 202
Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
Lucie Heinzerling, Thomas Eigentler, Michael Fluck, et al.
ESMO Open (2019) Vol. 4, Iss. 3, pp. e000491-e000491
Open Access | Times Cited: 185
Clinical and Morphologic Characteristics of MEK Inhibitor–Associated Retinopathy
Jasmine H. Francis, Larissa A. Habib, David H. Abramson, et al.
Ophthalmology (2017) Vol. 124, Iss. 12, pp. 1788-1798
Open Access | Times Cited: 116
OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS
Silvia Méndez-Martínez, Pilar Calvo, Óscar Ruiz‐Moreno, et al.
Retina (2019) Vol. 39, Iss. 8, pp. 1435-1450
Closed Access | Times Cited: 96
The Use of MEK Inhibitors in Neurofibromatosis Type 1–Associated Tumors and Management of Toxicities
Laura J. Klesse, Justin T. Jordan, Heather B. Radtke, et al.
The Oncologist (2020) Vol. 25, Iss. 7, pp. e1109-e1116
Open Access | Times Cited: 76
MAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges
Petros Moustardas, Daniel Aberdam, Neil Lagali
Cells (2023) Vol. 12, Iss. 4, pp. 617-617
Open Access | Times Cited: 25
Systemic Treatment of Melanoma
Reinhard Dummer, Simone M. Goldinger
(2024), pp. 1-15
Closed Access | Times Cited: 10
Drug-related macular edema: a real-world FDA Adverse Event Reporting System database study
Xiang Li, Yali Sun, Q. Huang, et al.
BMC Pharmacology and Toxicology (2025) Vol. 26, Iss. 1
Open Access | Times Cited: 1
Integrating MAPK pathway inhibition into standard-of-care therapy for pediatric low-grade glioma
Erin E. Crotty, Aimee Sato, Mohamed S Abdelbaki
Frontiers in Oncology (2025) Vol. 15
Open Access | Times Cited: 1
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management
Helen Gogas, Keith T. Flaherty, Reinhard Dummer, et al.
European Journal of Cancer (2019) Vol. 119, pp. 97-106
Open Access | Times Cited: 72
Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study
Christina Guo, Maxime Chénard-Poirier, Desamparados Roda, et al.
The Lancet Oncology (2020) Vol. 21, Iss. 11, pp. 1478-1488
Closed Access | Times Cited: 58
Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Ronald S. Go, Eric D. Jacobsen, Robert A. Baiocchi, et al.
Journal of the National Comprehensive Cancer Network (2021) Vol. 19, Iss. 11, pp. 1277-1303
Open Access | Times Cited: 53
Ocular Toxicity of Targeted Anticancer Agents
Blake H. Fortes, Prashant D. Tailor, Lauren A. Dalvin
Drugs (2021) Vol. 81, Iss. 7, pp. 771-823
Closed Access | Times Cited: 38
A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic BRAF-Mutated Thyroid Cancer in Japan
Makoto Tahara, Naomi Kiyota, Hiroo Imai, et al.
Thyroid (2024)
Open Access | Times Cited: 5
Targeted treatment for craniopharyngioma
Natalie E Stec, Fred G. Barker, Priscilla K. Brastianos
Journal of Neuro-Oncology (2025)
Closed Access
Incidence and Management of Retinopathy and Uveitis in Patients Receiving BRAF/MEK Inhibitor Therapy
Isana Nakajima, Koji Yoshino, Hideki Tsuji
Seminars in Ophthalmology (2025), pp. 1-7
Closed Access
Neoplasia and intraocular inflammation: From masquerade syndromes to immunotherapy-induced uveitis
Sara Touhami, Isabelle Audo, C. Terrada, et al.
Progress in Retinal and Eye Research (2019) Vol. 72, pp. 100761-100761
Closed Access | Times Cited: 41
The unjustified fear of erdafitinib induced central serous retinopathy
Pieter‐Paul Schauwvlieghe, Freya Peeters, Michiel Strijbos, et al.
Annals of Oncology (2025)
Closed Access
New features in MEK retinopathy
Pallavi Tyagi, Cynthia Santiago
BMC Ophthalmology (2018) Vol. 18, Iss. S1
Open Access | Times Cited: 34
Retinal toxicities of systemic anticancer drugs
Supriya Arora, Thamolwan Surakiatchanukul, Tarun Arora, et al.
Survey of Ophthalmology (2021) Vol. 67, Iss. 1, pp. 97-148
Closed Access | Times Cited: 26
Retinal Toxicity Induced by Chemical Agents
Daniel Souza Monteiro de Araújo, Rafael Brito, Danniel Pereira‐Figueiredo, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8182-8182
Open Access | Times Cited: 17
Ocular adverse events associated with BRAF and MEK inhibitor combination therapy: a pharmacovigilance disproportionality analysis of the FDA adverse event reporting system
Shuohan Huang, Zihan Guo, Mengmeng Wang, et al.
Expert Opinion on Drug Safety (2023) Vol. 22, Iss. 2, pp. 175-181
Open Access | Times Cited: 9
FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA
Akosua Nti, Leona Serrano, Harpal S. Sandhu, et al.
Retina (2018) Vol. 39, Iss. 3, pp. 502-513
Open Access | Times Cited: 28
Update on Retinal Drug Toxicities
S. Tammy Hsu, Arathi Ponugoti, Jordan D. Deaner, et al.
Current Ophthalmology Reports (2021) Vol. 9, Iss. 4, pp. 168-177
Open Access | Times Cited: 20
Page 1 - Next Page

Scroll to top